ImmunityBio, Inc. (IBRX) intrinsic value & 10-year financials
ImmunityBio, Inc. (IBRX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 139.3% a year to $113.3M, with an average return on invested capital of 29.0%.
- Graham intrinsic value
- —
- Share price (Oct 20, 2026)
- $8.42
- Market cap
- $7.7B
- Revenue (FY2025)
- $113.3M
- Revenue growth (10-yr CAGR)
- 139.3%
- ROIC (10-yr avg)
- 29.0%
- Free cash flow (FY2025)
- -$308.8M
IBRX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $113.3M | -$351.4M | -$0.38 | -$308.8M | -226.0% | 44.4% |
| FY2024 | $14.7M | -$413.6M | -$0.62 | -$398.1M | -2334.2% | 48.8% |
| FY2023 | $622.0K | -$583.2M | -$1.15 | -$397.3M | -58239.5% | 81.9% |
| FY2022 | $240.0K | -$416.6M | -$1.04 | -$415.7M | -146374.2% | 153.3% |
| FY2021 | $934.0K | -$346.8M | -$0.89 | -$308.0M | -35361.9% | 250.1% |
| FY2020 | $111.0K | -$92.4M | -$0.59 | -$73.1M | -82545.9% | -76.9% |
| FY2019 | $43.0K | -$65.8M | -$0.43 | -$65.5M | -157690.7% | -55.2% |
| FY2018 | $47.0K | -$96.2M | — | -$76.5M | -209338.3% | -75.8% |
| FY2017 | $45.0K | -$96.4M | — | -$83.6M | -220266.7% | -38.5% |
| FY2016 | $44.0K | -$120.8M | — | -$45.2M | -282954.5% | -42.2% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ImmunityBio, Inc. is a consistent compounder, expanding top-line revenue at 139.3% annually over the past decade.
ImmunityBio, Inc. has historically struggled to out-earn its cost of capital, averaging just -3.6% ROIC.
ImmunityBio, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, ImmunityBio, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-12.62 per share.